Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response

Lung. 2018 Dec;196(6):673-680. doi: 10.1007/s00408-018-0153-3. Epub 2018 Sep 3.


Background: The β2-adrenergic receptor gene is one of the most extensively studied genes with respect to asthma prevalence and severity. The Arg16Gly and Gln27Glu polymorphisms in the β2-adrenergic receptor gene cause changes in the amino acids sequence of the receptor which may cause alteration in response to bronchodilators and the risk of asthma.

Objective: The purpose of the study was to determine the association between β2-adrenergic receptor gene polymorphisms and asthma risk, severity and response to therapy.

Subjects and methods: 58 asthmatic patients and 38 healthy subjects were included. The β2-adrenergic receptor polymorphisms genotyping was done using Real-Time polymerase chain reaction.

Results: The allelic frequencies for the Arg16Gly polymorphism were 15.5%, 48.3%, and 36.2% for the homozygous A wild, heterozygous, and homozygous G mutant alleles in asthmatics (P < 0.01) and 5.3%, 47.4%, and 47.4% in healthy subjects (P < 0.01). For the Gln27Glu polymorphism, the allelic frequencies for the homozygous C wild, heterozygous and homozygous G mutant alleles were 51.7%, 41.4%, and 6.9% in asthmatics (P < 0.01) and 44.7%, 39.5%, and 15.8% in healthy subjects (P < 0.01). The heterozygous Arg16Gly and Gln27Glu were found in most of severe asthma cases (7/13, 53.8% each). While homozygous wild and mutant seemed to be protective and associated with mild disease in both alleles. Finally, 75% of Arg16Gly heterozygous group were good responders (P < 0.01), 81% of homozygous G mutant were bad responders. For Gln27Glu polymorphism, 60% of C wild group were good responders and 75% of G mutant group were bad responders.

Conclusions: The findings suggest that the Arg16Gly and Gln27Glu polymorphisms in the β2-AR gene are associated with asthma severity and response to therapy and might be used in personalized treatment for these patients in the future. This work is registered in with ID: NCT03118869.

Keywords: Asthma; Egyptian; Polymorphisms; Response; Severity; β2-adrenoreceptor.

MeSH terms

  • Adolescent
  • Adult
  • Asthma / drug therapy*
  • Asthma / genetics*
  • Case-Control Studies
  • Female
  • Gene Frequency
  • Heterozygote
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Receptors, Adrenergic, beta-2 / genetics*
  • Risk Factors
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult


  • Receptors, Adrenergic, beta-2

Associated data